Skip to Content
Stock Analyst Update

Procter & Gamble Works to Stem Tide of Share Losses

Investors would be wise to stock up while shares trade at a 15%-20% discount to our valuation.

Mentioned:

The main question leading up to  Procter & Gamble’s (PG) fourth-quarter results centered on the company's ability to boost sales and market share amid the industry's tepid pricing and competitive pressures. Organic sales ticked up just 1% in the quarter, driven entirely by increased volume; as has been the case, performance was weighed down by grooming (10% of sales) and baby (27%), which were each lower by 2%-3% on an organic basis. Excluding these two segments, sales popped more than 3%, with beauty (one fifth of sales) again the standout, up 7%. Management highlighted sequential market share improvement across the majority of its mix, a shift from the recent past, when share gains proved elusive on a consolidated basis. We think this gives credence to P&G's past strategic endeavors to rightsize its brand mix (culling more than 100 brands) and funnel added resources to support the brand intangible assets, particularly its entrenched retail relationships, that underlie our wide moat rating.

We don’t think P&G is opting for top-line gains at any cost. The firm is working to extract another $10 billion in costs, aiming to reduce overhead, lower material costs, and increase manufacturing and marketing productivity; this positively affected gross margins by 270 basis points. However, this gain was offset by higher input and transportation costs (110 basis points), unfavorable mix (120 basis points), lower pricing (80 basis points), foreign exchange (40 basis points), and one-time investments (60 basis points), leaving adjusted gross margins 140 basis points lower at just under 48%.

With fiscal 2018 results and 2019 guidance in line with our outlook, we see little change to our $98 fair value estimate, which is based on 3%-4% annual average sales growth and operating margins approaching the mid-20s over the next decade. The shares trade at a 15%-20% discount to our valuation, and with a nearly 4% dividend yield, we think investors would be wise to stock up.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Erin Lash does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.